2,233
Views
5
CrossRef citations to date
0
Altmetric
Research Paper

Evaluation of a risk score to predict future Clostridium difficile disease using UK primary care and hospital data in Clinical Practice Research Datalink

, ORCID Icon, , &
Pages 2475-2481 | Received 21 Dec 2018, Accepted 24 Feb 2019, Published online: 04 Apr 2019

References

  • Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccin Immunother. 2014;10(6):1466–77. doi:10.4161/hv.28428.
  • Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539–48. doi:10.1056/NEJMra1403772.
  • Public Health England. Updated guidelines on the management and treatment of C. diff infection. 2013. [accessed 2017 May 7]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/321891/Clostridium_difficile_management_and_treatment.pdf.
  • Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–34. doi:10.1056/NEJMoa1408913.
  • Ofori E, Ramai D, Dhawan M, Mustafa F, Gasperino J, Reddy M. Community-acquired Clostridium difficile: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. J Hosp Infect. 2018;99(4):436–42. doi:10.1016/j.jhin.2018.01.015.
  • Baggs J, Yousey-Hindes K, Ashley ED, Meek J, Dumyati G, Cohen J, Wise ME, McDonald LC, Lessa FC. Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials. Vaccine. 2015;33(46):6241–49. doi:10.1016/j.vaccine.2015.09.078.
  • Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J Infect. 2013;66(2):115–28. doi:10.1016/j.jinf.2012.10.019.
  • Butt E, Foster JA, Keedwell E, Bell JE, Titball RW, Bhangu A, Michell SL, Sheridan R. Derivation and validation of a simple, accurate and robust prediction rule for risk of mortality in patients with Clostridium difficile infection. BMC Infect Dis. 2013;13:316. doi:10.1186/1471-2334-13-316.
  • Chandra S, Latt N, Jariwala U, Palabindala V, Thapa R, Alamelumangapuram CB, Noel M, Marur S, Jani N. A cohort study for derivation and validation of a clinical prediction scale for hospital-onset Clostridium difficile infection. Can J Gastroenterol. 2012;26:885–88.
  • Chandra S, Thapa R, Marur S, Jani N. Validation of a clinical prediction scale for hospital-onset Clostridium difficile infection. J Clin Gastroenterol. 2014;48(5):419–22. doi:10.1097/mcg.0000000000000012.
  • Dubberke ER, Yan Y, Reske KA, Butler AM, Doherty J, Pham V, Fraser VJ. Development and validation of a Clostridium difficile infection risk prediction model. Infect Control Hosp Epidemiol. 2011;32(4):360–66. doi:10.1086/658944.
  • Dubberke ER, Olsen MA, Stwalley D, Kelly CP, Gerding DN, Young-Xu Y, Mahe C. Identification of Medicare recipients at highest risk for Clostridium difficile infection in the US by population attributable risk analysis. PLoS One. 2016;11(2):e0146822. doi:10.1371/journal.pone.0146822.
  • Hebert C, Du H, Peterson LR, Robicsek A. Electronic health record-based detection of risk factors for Clostridium difficile infection relapse. Infect Control Hosp Epidemiol. 2013;34(4):407–14. doi:10.1086/669864.
  • Hensgens MP, Dekkers OM, Goorhuis A, LeCessie S, Kuijper EJ. Predicting a complicated course of Clostridium difficile infection at the bedside. Clin Microbiol Infect. 2014;20(5):O301–8. doi:10.1111/1469-0691.12391.
  • Kassam Z, Cribb, Fabersunne C, Smith MB, Alm EJ, Kaplan GG, Nguyen GC, Ananthakrishnan AN. Clostridium difficile associated risk of death score (CARDS): A novel severity score to predict mortality among hospitalised patients with C. difficile infection. Aliment Pharmacol Ther. 2016;43(6):725–33. doi:10.1111/apt.13546.
  • Khanafer N, Vanhems P, Barbut F, Luxemburger C, Demont C, Hulin M, Dauwalder O, Vandenesch F, Argaud L, Badet L, et al. Factors associated with Clostridium difficile infection: A nested case-control study in a three year prospective cohort. Anaerobe. 2017;44:117–23. doi:10.1016/j.anaerobe.2017.03.003.
  • Kuntz JL, Johnson ES, Raebel MA, Platt RW, Petrik AF, Yang X, Thorp ML, Spindel SJ, Neil N, Smith DH. Predicting the risk of Clostridium difficile infection following an outpatient visit: development and external validation of a pragmatic, prognostic risk score. Clin Microbiol Infect. 2015;21(3):256–62. doi:10.1016/j.cmi.2014.11.001.
  • Kuntz JL, Smith DH, Petrik AF, Yang X, Thorp ML, Barton T, Barton K, Labreche M, Spindel SJ, Johnson ES. Predicting the risk of Clostridium difficile infection upon admission: A score to identify patients for antimicrobial stewardship efforts. Perm J. 2016;20(1):20–25. doi:10.7812/tpp/15-049.
  • LaBarbera FD, Nikiforov I, Parvathenani A, Pramil V, Gorrepati S. A prediction model for Clostridium difficile recurrence. J Community Hosp Intern Med Perspect. 2015;5(1):26033. doi:10.3402/jchimp.v5.26033.
  • Miller MA, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, Kean Y, Sears P. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013;13:148. doi:10.1186/1471-2334-13-148.
  • Shivashankar R, Khanna S, Kammer PP, Scott Harmsen W, Zinsmeister AR, Baddour LM, Pardi DS. Clinical predictors of recurrent Clostridium difficile infection in out-patients. Aliment Pharmacol Ther. 2014;40(5):518–22. doi:10.1111/apt.12864.
  • Stites SD, Cooblall CA, Aronovitz J, Singletary SB, Micklow K, Sjeime M. The tipping point: patients predisposed to Clostridium difficile infection and a hospital antimicrobial stewardship programme. J Hosp Infect. 2016;94(3):242–48. doi:10.1016/j.jhin.2016.07.022.
  • Tabak YP, Johannes RS, Sun X, Nunez CM, McDonald LC. Predicting the risk for hospital-onset Clostridium difficile infection (HO-CDI) at the time of inpatient admission: HO-CDI risk score. Infect Control Hosp Epidemiol. 2015;36(6):695–701. doi:10.1017/ice.2015.37.
  • van Werkhoven CH, van der Tempel J, Jajou R, Thijsen SF, Diepersloot RJ, Bonten MJ, Postma DF, Oosterheert JJ. Identification of patients at high risk for Clostridium difficile infection: development and validation of a risk prediction model in hospitalized patients treated with antibiotics. Clin Microbiol Infect. 2015;21(8):786 e1–8. doi:10.1016/j.cmi.2015.04.005.
  • Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Development and validation of a recurrent Clostridium difficile risk-prediction model. J Hosp Med. 2014;9(7):418–23. doi:10.1002/jhm.2189.
  • Friedman HS, Navaratnam P, Reardon G, High KP, Strauss ME. A retrospective analysis of clinical characteristics, hospitalization, and functional outcomes in residents with and without Clostridium difficile infection in US long-term care facilities. Curr Med Res Opin. 2014;30(6):1121–30. doi:10.1185/03007995.2014.895311.
  • Stevens V, Concannon C, van Wijngaarden E, McGregor J. Validation of the chronic disease score-infectious disease (CDS-ID) for the prediction of hospital-associated Clostridium difficile infection (CDI) within a retrospective cohort. BMC Infect Dis. 2013;13:150. doi:10.1186/1471-2334-13-150.
  • Yu H, Baser O, Wang L. Burden of Clostridium difficile-associated disease among patients residing in nursing homes: a population-based cohort study. BMC Geriatr. 2016;16(1):193. doi:10.1186/s12877-016-0367-2.
  • Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill. 2008;13(31): 1–9.
  • McGee S. Simplifying likelihood ratios. J Gen Intern Med. 2002;17(8):646–49. doi:10.1046/j.1525-1497.2002.10750.x.
  • Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data resource profile: clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–36. doi:10.1093/ije/dyv098.
  • The Clinical Practice Research Datalink; [ accessed 2014 May 10]. www.cprd.com.
  • Campbell J, Dedman DJ, Eaton SC, Gallagher AM, Williams TJ. Is the CPRD Gold population comparable to the UK population? Pharmacoepidemiol Drug Saf. 2013;22:280–81.